A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms

AIDS Research and Human Retroviruses

Volumn 21, Issue 11, 2005, Pages 933-939

  Ross, Lisa ^a   Boulmé, Roman ^b   Fisher, Robin ^a   Hernandez, Jaime ^a   Florance, Allison ^a   Schmit, Jean Claude ^c   Williams, Vanessa ^a  

^a GLAXOSMITHKLINE   (United States)

^b Advanced Biological Laboratories (ABL) Luxembourg   (Luxembourg)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ALGORITHM; ARTICLE; ASSAY; COMPARATIVE STUDY; CORRELATION COEFFICIENT; DRUG CLASSIFICATION; DRUG SENSITIVITY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METHODOLOGY; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL;

EID: 28944450744     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.933     Document Type: Article

References (30)

1. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al.: Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-128.
2. The EuroGuidelines Group for HIV Resistance: Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting. AIDS 2001;15:309-320.
3. Vandamme AM, Houyez F, Banhegyi D, Clotet B, De Schrijver G, De Smet KA, et al.: Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antiviral Ther 2001;6:21-39.
4. Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R, et al.: World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing. AIDS 2001;15:1671-1677.
5. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, et al.: A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42:269-276.
6. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chermother 2000;44:920-928.
7. Race E, Dam E, Obry V, Paulous S, and Clavel F: Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999;13:2061-2068.
8. Schmidt B, Walter H, Zeitler N, and Korn K: Genotypic drug resistance interpretation systems-the cutting edge of antiretroviral therapy. AIDS Rev 2002;4:148-156.
9. De Luca A and Perno CF: Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing. Curr Opin Infect Dis 2003;16:573-580.
10. Beerenwinkel N, Daumer M, Oette M, Korn K, Hoffmann D, Kaiser R, et al.: Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003;31:3850-3855.
11. Betts BJ and Shafer RW: Algorithm specification interface for human immunodeficiency virus type 1 genotypic interpretation. J Clin Microbiol 2003;41:2792-2794.
12. De Luca A, Antinori A, Di Giambenedetto S, Cingolani A, Colafigli M, and Perno CF, et al.: Interpretation systems for genotypic drug resistance of HIV-1. Scand J Infect Dis 2003;35(Suppl. 106):29-34.
13. DiRienzo AG, DeGruttola V, Larder B, and Hertogs K: Non-parametric methods to predict HIV drug susceptibility phenotype from genotype. Stat Med 2003;22:2785-2798.
14. Foulkes AS and De GV: Characterizing the relationship between HIV-1 genotype and phenotype: Prediction-based classification. Biometrics 2002;58:145-156.
15. Gallego O, Martin-Carbonero L, Aguero J, Mendoza CC, Corral A, and Soriano V: Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. J Virol Methods 2004;121:115-118.
16. Ross L, Scarsella A, Raffanti S, Henry K, Becker S, Fisher R, et al.: Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Res Hum Retroviruses 2001;17:1107-1115.
17. Rousseau MN, Vergne L, Montes B, Peeters M, Reynes J, Delaporte E, et al.: Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;26:36-43.
18. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al.: Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 2002;16:727-736.
19. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, and Vandamme AM: A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antiviral Ther 2002;7:123-129.
20. MacArthur RD: An updated guide to genotype interpretation. AIDS Read 2004;14:256-258.
21. MacArthur RD: Drug resistance. An updated, user-friendly guide to genotype interpretation. AIDS Read 2000;10:652-657.
22. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:920-928.
23. Fleiss J: Statistical Methods for Rate and Proportion. Wiley-Interscience, New York, 1981, pp. 212-236.
24. Qari SH, Respess R, Weinstock H, Beltrami EH, Hertogs K, Larder BA, et al.: Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J Clin Microbiol 2002;40:31-35.
25. Bacheler C, Winters B, Harrigan R, Perez-Elias M, Miller M, Emery S, van Leth F, Robinson P, and Baxter JD, and Pozniak A: Estimation of phenotypic clinical cut-offs for virco TYPE HIV-1 through meta analyses of clinical trial cohort data. 44th ICAAC, Washington, DC, Abstract H-1133, 2004.
26. Ravela J, Betts BJ, Brun-Vezinet F, Vandamme AM, Descamps D, Van Laethem K, et al.: HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 2003;33:8-14.
27. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al.: Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002;16:1511-1519.
28. De Luca A and Perno CF: Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing. Curr Opin Infect Dis 2003;16:573-580.
29. De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, Rizzo MG, et al.: Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003;187:1934-1943.
30. Sturmer M, Doerr HW, Staszewski S, and Preiser W: Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antiviral Ther 2003;8:239-244.